Clinical trial NCT06378957: Behavioral Pharmacology of Orally Administered THC and D-limonene
Official title: Behavioral Pharmacology of Orally Administered THC and D-limonene
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Subjective Drug Effects
THC
D-limonene
Lead sponsor: Johns Hopkins University
Sponsor class: OTHER
First posted: 2024-04-23
Enrollment: 65
Sex: ALL
Minimum age (years): 21
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Within-subjects design where participants are randomly assigned to dose conditions
Primary purpose: BASIC_SCIENCE

Brief summary: The current clinical trial will investigate the effects of orally administered d-limonene (limonene), delta-9-tetrahydrocannabinol (THC) and the combination in healthy adult volunteers.

Detailed description: The current clinical trial will investigate the interaction of orally administered d-limonene (limonene) and delta-9-tetrahydrocannabinol (THC). Limonene is a flavor/fragrance component common to many plants, including cannabis. The investigators have previously demonstrated that vaporized limonene can impact the acute effects of THC. The purpose of this study is to examine whether orally administered limonene modulates the acute effects of orally co-administered THC in a manner similar to when these substances are inhaled A controlled laboratory study will be completed at Johns Hopkins evaluating placebo, THC alone, and four ascending doses of d-limonene in combination with THC. Participants will be healthy adults with experience using cannabis. A total of 6 outpatient drug administration sessions will be conducted for each evaluable participant. The investigators will recruit study volunteers until 20 participants complete the protocol.

Eligibility criteria: Inclusion Criteria:

* Have provided written informed consent
* Be between the ages of 21 and 55
* Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests
* Test negative for drugs of abuse other than cannabis, including breath alcohol at the screening visit and at clinic admission
* Not be pregnant or nursing (if female). All females must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at clinic admission.
* Have a body mass index (BMI) in the range of 18 to 36 kg/m2
* Blood pressure at Screening Visit does not exceed a systolic blood pressure (SBP) of 150 mmHg or a diastolic blood pressure (DBP) of 90 mmHg
* Have no allergies to any of the ingredients used to prepare (cellulose, THC, d-limonene).
* Report having used a high THC cannabis product in the past 3 years and having experienced anxiety after consuming cannabis at least once in lifetime.

Exclusion Criteria:

* Non-medical use of psychoactive drugs other than, nicotine, alcohol, or caffeine 3 month prior to the Screening Visit;
* History of or current evidence of significant medical (e.g. seizure disorder) or psychiatric illness (e.g. psychosis) judged by the investigator to put the participant at greater risk of experiencing an adverse event due to exposure or completion of other study procedures.
* Use of an over the counter (OTC), systemic or topical drug(s), herbal supplement(s), or vitamin(s) within 14 days of experimental sessions; which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the subject.
* Use of a prescription medication (with the exception of birth control prescriptions) within 14 days of experimental sessions; which, in the opinion of the investigator or sponsor, will interfere with the study result or the safety of the subject.
* Average use of cannabis more than 2 times per week in the prior 3 months.
* History of clinically significant cardiac arrhythmias or vasospastic disease (e.g., Prinzmetal's angina).
* Enrolled in another clinical trial or have received any drug as part of a research study within 30 days prior to dosing.
* Individuals with anemia or who have donated blood in the prior 30 days

Primary outcomes:
measure: Subjective Drug Effect as assessed by Visual Analog Scale
timeFrame: 8 hours after dosing
Secondary outcomes:
measure: Subjective Drug Liking as assessed by Visual Analog Scale
timeFrame: 8 hours after dosing
measure: Subjective anxiety as assessed by Visual Analog Scale
timeFrame: 8 hours after dosing
measure: Subjective hunger as assessed by Visual Analog Scale
timeFrame: 8 hours after dosing
measure: Subjective paranoia as assessed by Visual Analog Scale
timeFrame: 8 hours after dosing
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: Johns Hopkins Behavioral Pharmacology Research Unit
state: Maryland
Study officials:
affiliation: Johns Hopkins School of Medicine
name: Austin Zamarripa, PhD
role: PRINCIPAL_INVESTIGATOR
References: